학술논문
LBA2 - Primary results of ALESIA: Phase III, randomised open-label study of alectinib (ALC) vs crizotinib (CRZ) in Asian patients (pts) with treatment-naïve ALK+ advanced non-small-cell lung cancer (NSCLC)
Document Type
Abstract
Author
Source
In Annals of Oncology November 2018 29 Supplement 9:ix174-ix174
Subject
Language
ISSN
0923-7534